Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – Alixorexton Was Generally Well Tolerated at All Doses Tested – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – Alkermes plc (Nasdaq: ALKS) […]